Neoadjuvant Anti-PD-1 Therapy Response in Oral Cavity Cancer, 12-Patient Cohort

12 individuals with resectable oral cavity squamous cell carcinoma were treated with neoadjuvant nivolumab, showing a 33% response rate. Researchers from UCLA analyzed longitudinal tumor and blood samples to identify molecular and immunological correlates of treatment response and recurrence. The study links specific genetic mutations and immune cell signatures to patient outcomes.

Use Cases

• Predicting immunotherapy response based on pretreatment tumor FLT4 mutations and PTEN signature enrichment mentioned in the description
• Modeling recurrence-free survival based on tumor mutational burden data described in the study
• Analyzing T cell receptor repertoire diversification in peripheral blood as a correlate of tumor response
• Investigating innate resistance mechanisms linked to CDKN2A, YAP1, or JAK2 mutations described in the data

Strengths

• Longitudinal data includes matched tumor and blood samples from the same 12 individuals.
• Analysis identifies specific genetic correlates (e.g., FLT4, PTEN) and immune signatures linked to clinical outcomes.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single, small cohort of 12 patients.

Provenance

Source

University of California, Los Angeles

Collection Method

Clinical study analyzing samples from a cohort of 12 patients.